Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 10, 1999, Pages 20-30

  Ereshefsky, Larry ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXAPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ERYTHROMYCIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; LORAZEPAM; LOXAPINE; LOXAPINE SUCCINATE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; QUETIAPINE; QUINOLONE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; TIOTIXENE; TRIFLUOPERAZINE;

ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYMPTOM; FIRST PASS EFFECT; HUMAN; HYDROXYLATION; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BINDING; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CARRIER PROTEINS; CLOZAPINE; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; LOXAPINE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; SCHIZOPHRENIA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0032909923     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38:S80-S88
2. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996;124:2-34
3. Ereshefsky L, Tran-Johnson T, Watanabe MD. Current concepts in the treatment of schizophrenia: the pathophysiologic basis for atypical antipsychotic efficacy. Clin Pharm 1996;8:680-707
4. Ereshefsky L, Watanabe MD, Tran-Johnson T. Clozapine: an atypical antipsychotic. Clin Pharm 1989;8:691-709
5. Kane JM. Schizophrenia. N Engl J Med 1996;334:34-41
6. Ereshefsky L. Treatment strategies for schizophrenia. Psychiatr Ann 1995; 25:285-296
7. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? a review of the evidence. Neuropsychopharmacology 1998; 18:63-101
8. Roth BL, Craigo SC. Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-1410
9. Ellenbroek BA, Lubbers LJ, Cools AR. Activity of "Seroquel" (ICI 204, 636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 1996;15:407-416
10. Miller AL, Ereshefsky L. Schizophrenia: how should we look at it? J Psychopharmacol 1997;11:21-23
11. Stahl S. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999;60 (suppl 10):31-41
12. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(suppl 10):5-14
13. Hue B, Palomba B, Giacarcly-Paty M, et al. Concurrent high-performance liquid chromatographic measurement of loxapine and amoxapine and of their hydroxylated metabolites in plasma. Ther Drug Monit 1998;20: 335-339
14. Cooper TB, Kelly RG. GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine. J Pharm Sci 1979;68:216-219
15. Cheung SW, Tang SW, Remington G. Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1991;564:213-221
16. Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982;4:33-40
17. Loxitane: Loxapine Succinate. Pearl River, NY: Medical Advisory Department, Lederle Laboratories; 1975;1-95
18. Coupet J, Rauh CE, Szues-Myers VA, et al. 2-Chloro-11-(1-piperazinyl) dibenz[b, f] [1, 4]oxazepine (amoxapine). an antidepressant with antipsychotic properties: a possible role for 7-OH-amoxapine. Biochem Pharmacol 1979;28:2514-2515
19. Beasley CM Jr, Tollefson G, Tran P, et al, and the Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
20. Owens MJ, Risch SC. Atypical antipsychotics. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998;323-343
21. Reynolds GP, Czudek C. New approaches to the drug treatment of schizophrenia. Adv Pharmacol 1995;32:461-501
22. Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73
23. 2 receptor antagonists: potential in the treatment of psychiatric disorders. CNS Drugs 1997;7:388-409
24. Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia [review]. J Clin Psychopharmacol 1998;18(2, suppl 1): 12S-19S
25. Feldman HS. Loxapine succinate as initial treatment of hostile and aggressive schizophrenic criminal offenders. J Clin Pharmacol 1982;22:366-370
26. Ward ME, Saklad SR, Ereshefsky L. Lorazepam for the treatment of psychotic agitation [letter]. Am J Psychiatry 1986;143:1195-1196
27. Ereshefsky L, Richards A. Psychosis. In: Koda-Kimble MA, Young LL, eds. Applied Therapeutics: The Clinical Use of Drugs, San Francisco, Calif: Applied Therapeutics Press; 1992;950-1001
28. Spivak B, Rotiman S, Vered Y, et al. Diminished aggressive and suicidal behavior, high plasma norepinephrine levels and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998;21:245-250
29. Cohen SA, Ihrig K, Lott RS, et al. Risperidone for aggression and self-injurious behavior in adults with mental retardation. J Autism Dev Disord 1998;28:229-233
30. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246
31. Arana GW, Ornsteen ML, Kanter F, et al. The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacol Bull 1986;22:77-87
32. Tonne U, Hiltunen AJ, Vikander B, et al. Neuropsychological changes during steady-state drug use, withdrawal and abstinence in primary benzodiazepine dependent patients. Acta Psychiatr Scand 1995;91:299-304
33. Nishiyama K, Sugishita M, Kurisaki H, et al. Reversible memory disturbances and intelligence impairment induced by long term anticholinergic therapy. Intern Med 1998;37:514-518
34. 2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997;154:1525-1529
35. Strange PG. Dissociation constants of neuroleptic drugs at dopamine receptors. Neuropsychopharmacology 1997;16:116-122
36. Bishop MP, Simpson GM, Dunnett CW, et al. Efficacy of loxapine in the treatment of paranoid schizophrenia. Psychopharmacology 1977;51: 107-112
37. Paprocki J, Barcala MP, Peixoto MD, et al. A controlled double blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients. Psychopharmacol Bull 1976;12:32-34
38. Moyano CZ. A double-blind comparison of Loxitane: loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients. Dis Nerv Syst 1975;36:301-304
39. Clark ML, Huber WK, Sullivan J, et al. Evaluation of loxapine succinate in chronic schizophrenia. Dis Nerv Syst 1972;33:783-791
40. James B, MacIntyre M, Hannah J. A study of parenteral loxapine succinate in very disturbed psychotic patients. N Z Med J 1982;95:123-124
41. Ereshefsky L, Lehmann CR, Saklad SR. Refractory patients and loxapine. Am J Psychiatry 1982;139:701-702
42. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-197
43. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-397
44. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind placebo controlled study. Br J Psychiatry 1997;171:569-573
45. Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991;43:587-604
46. Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 1997;42:529-545
47. 2 dopamine receptors. Br J Pharmacol 1997;121:731-736
48. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 1993;236:483-486
49. 4 receptors: potential therapeutics implications in the treatment of schizophrenia. CNS Drugs 1997;8:1-11
50. Tran PV, Hamilton SH, Kuntz AJ, et al. Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
51. Conley RR, Brecher M, and the Risperidone/Olanzapine Study Group. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Presented at the 11th Congress of the European College of Neuropsychopharmacology; October 31-November 4, 1998; Paris, France
52. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791
53. Selman FB, McClure RF, Helwig H. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics. Curr Ther Res Clin Exp 1976;19:645-652
54. Heel RC, Brogden RN, Speight TM, et al. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs 1978;15:198-217
55. Filho UV, Versiani CV, Romildo-Bueno J. The efficacy and safety of loxapine succinate in the treatment of schizophrenia: a comparative study with thiothixene. Curr Ther Res Clin Exp 1975;18:476-479
56. Chouinard G, Annable L, DeMontigny C, et al. Loxapine succinate in the treatment of newly admitted schizophrenic patients. Curr Ther Res Clin Exp 1977;21:73-79
57. Brauzer B, Goldstein BJ, Steinbook RM, et al. The treatment of mixed anxiety and depression with loxapine: a controlled comparative study. J Clin Pharmacol 1974;14:455-458
58. Charlalampous KD, Freemesser GF, Smalling KF. A double-blind controlled study of loxapine succinate in the treatment of anxiety neurosis. J Clin Pharmacol 1974;14:464-469
59. Claghorn JL. A comparative study of loxapine succinate, librium, and placebo in neurotic outpatients. Curr Ther Res Clin Exp 1973;15:8-12
60. Goldschmidt TJ, Burch EA. Use of loxapine to treat a patient with psychotic depression. Am J Psychiatry 1982;139:946-947
61. Burch EA, Hubbard RW, Goldschmidt TJ. Loxapine in the treatment of psychotic-depressive disorders: measurement of antidepressant metabolites. South Med J 1983;76:991-995
62. Gojer JAC. Possible manic side-effects of loxapine. Can J Psychiatry 1992; 37:669-670
63. Battaglia J, Thornton L, Young C. Loxapine-lorazepam-induced hypotension and stupor [letter]. J Clin Psychopharmacol 1989;9:227
64. Chong LS, Abbott PM. Neuroleptic malignant syndrome secondary to loxapine. Br J Psychiatry 1991;159:572-573
65. Crow T. The two syndrome concept: origins and current status. Schizophr Bull 1985;11:471-476
66. Gibaldi M, Perrier D. Pharmacokinetics: Drugs and the Pharmaceutical Sciences, vol 15. New York, NY: Marcel Dekker; 1982:5-25
67. Loxitane [package insert]. Corona, Calif. Watson Laboratories, Inc; 1997
68. Simpson GM, Cooper TB, Lee JH, et al. Clinical and plasma level characteristics of IM and oral loxapine. Psychopharmacology 1978;56:225-232
69. Burch EA, Goldschmidt TJ. Measurement of antidepressant metabolites in patients treated with loxapine. Presented at the 138th annual meeting of the American Psychiatric Association; May 18-24, 1985; Dallas, Tex
70. Ereshefsky L, Jann MW, Saklad SR, et al. Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J Clin Psychiatry 1986;47(9, suppl):6-15
71. Ereshefsky L. Toxicities of amoxapine. Clin Pharm 1983;2:104-108
72. Ketchum C, Robinson CA, Scott JW. Analysis of amoxapine, 8-hydroxyamoxapine and maprotiline by high-pressure liquid chromatography. Ther Drug Monit 1983;5:309-312
73. Kobayashi A, Sugita S, Nakazawa K. Determination of amoxapine and its metabolites in human serum by high-performance liquid chromatography. Neuropharmacology 1995;24:1253-1256
74. Tasset JJ, Hassan FM. Liquid-chromatographic determination of amoxapine and 8-hydroxyamoxapine in human serum. Clin Chem 1982;28: 2154-2157
75. Ereshefsky L, Saklad SR, Jann MW, et al. Pharmacokinetics of fluphenazine by high performance thin layer chromatography [abstract]. Drug Intell Clin Pharm 1983;17:436
76. Ereshefsky L, Davis CM, Harrington CA, et al. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol 1984;4:138-142
77. Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984;45(5 pt 2):50-59
78. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57(suppl 11):12-25
79. McCreadie RG, Mackie M, Wiles DH, et al. Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. Br J Psychiatry 1984;144:625-629
80. Schatzberg AF, DeBattista C, Ereshefsky L, et al. Current psychotropic dosing and monitoring guidelines. Prim Psychiatry 1997;4:35-63
81. Ereshefsky L. Drug interactions of antidepressants. Psychiatr Ann 1996;26: 342-350
82. Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991;11:296-301
83. Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985;5:106-109
84. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996;57(suppl 8):17-24
85. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996;16:177-187
86. Guttendorf RJ, Wedlund PJ. Genetic aspects of drug disposition and therapeutics. Br J Clin Pharmacol 1992;32:107-117
87. Linnoila M, Viukari M, Vaisanen K, et al. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980;137: 819-821
88. Jann MW, Saklad SR, Ereshefsky L, et al. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 1986;90:468-470
89. Ereshefsky L, Jann MW, Saklad SR, et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985;20:329-352
90. Stimmel GL, Falloon IR. Chlorpromazine plasma levels, adverse effects and tobacco smoking: case report. J Clin Psychiatry 1983;44:420-422